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Introduction
Kidney disease in humans is such a prevalent issue, especially with regards to aging
populations, that there is a distinct qualifier for Medicare (in the United States) made just for
patients with end-stage renal disease (ESRD). Chronic kidney disease is so prevalent, in fact,
that even though medical technology has advanced greatly in the last few decades, clinicallydefined kidney disease has only fallen from over 10.0% prevalence in all U.S. adults aged 20-65
down to 6.9% in adults as of 20161,2. Among all of these patients, some develop a loss in renal
function through other medical conditions, such as diabetes, obesity, or hypertension, which has
gained increased awareness in recent years. Others, however, come across their loss in
function through genetics and mutations rather than from other health issues normally
associated with more aged individuals. One such genetic function is called Alport Syndrome,
which affects about 0.2% of adults, as well as about 3% of children in the U.S., around 1 in
5,000 births3,4. Studies of Alport Syndrome (AS) at the genetic level have revealed much about
the nature of this syndrome and about the mechanism of kidney disease as an umbrella term,
starting well before the turn of the 21st century and continuing today. Herein is a report detailing
a review of the history of such studies, major turning points in the progressive battle against AS,
how clinical medicine has advanced as a result, and what the cutting edge of research means
for the future of not only AS, but many other forms of kidney disease and other genetic
diseases.
Initial Research - Finding Alport Syndrome

Chronic kidney disease, as a general blanket category of diseases, has been studied
throughout modern history, with published medical studies identifying kidney syndromes or
diseases dating back to the 19th century, with observations dating well before4,5,. While
rudimentary for the most part, and lacking modern technologies or even simple light microscopy,
such studies were able to direct observations toward a trend of symptoms linked to patients with
kidney disease, such as proteinuria, hematuria and atrophied kidneys via postmortem
autopsies3-12. Strikingly, even though no thorough imaging or screening tests existed at the time,
these consistent observations by Dr. Richard Bright, Domenico Cotugno, and others dating from
the late 16th century onwards prompted additional study throughout the 19th and 20th
centuries13,14. At this point in history, forms of chronic kidney disease were identified due to the
distinct excretion of protein and the formation of urinary sediment, such as uric acid
crystallization13,14. However, genetic diseases such as Alport Syndrome had not been
documented yet, and would not be until more effective detection methods became available and
genetic disease as a whole became a more relevant field of research, despite the results that
Gregor Mendel published in 1866 that would set the standards for modern genetics, a nowfamous experiment taught in every biology class15.

Today, most biology textbooks note that the studies published by Mendel went largely
unnoticed until the turn of the 20th century, when methodology surrounding modern genetics
was said to have been “rediscovered”. Namely, in conjunction with Friedrich Miescher’s
discovery of DNA in 1869, independent study from three botanists by the names of Hugo
DeVries, Carl Correns and Erich von Tschermak, were able to achieve results confirming the
rules for genetic inheritance as observed by Mendel at the turn of the 20th century, and their
papers publishing these findings helped greatly to solidify the base of what we know as modern
genetics16-19. In the decade following the publication of these results, there was something of a
revelation in this new field; the term “gene” was coined by Wilhelm Johannsen in 1909, and just

seven years earlier was the advent of observed genetic inheritance in the form of hereditary
disease, along with publication of chromosome theory by Archibald Garrod and Walter Sutton
respectively. Of course, we have now learned how lucky Mendel and his contemporaries were
when it came to their observations of genetics in action; independent loci on autosomal
chromosomes with only two distinct alleles in diploid organisms is a specific combination that
can be observed as its own system because no cross-analysis must be performed with other
variables, such as a third allele, locus, or a regulatory gene in another location entirely, let alone
traits with incomplete or codominant phenotypic behavior or other inheritance patterns. While at
this point researchers were aware that DNA existed and formed tightly packed chromosomes
(though Watson, Crick, and Franklin had not started their work on elucidation of nucleic acid
structure yet), nobody had attributed hereditary genes, or even traits generally, to a specific
chromosome until Thomas Hunt Morgan published his study of fruit flies (Drosophila
melanogaster) and directly linked expression of eye color to fruit flies’ X chromosomes. The
results of this one study were certainly unprecedented, and one consequence was the advent of
techniques such as pedigree charts within families for scientists and counselors to deduce
inheritance patterns over multiple generations with minimal information as opposed to genome
sequencing, which would come about as a method far later into the 20th century. The
aforementioned studies were all highly influential in allowing the discovery of Alport Syndrome,
detailed herein.

Alport Syndrome, as described previously, is a genetic disorder that affects around 1 in
every 5,000 individuals in the United States, and it is characterized by symptoms related to
chronic kidney disease (CKD), such as proteinuria, hematuria, and in many cases symptoms of
moderate hearing loss and moderate vision loss that manifest in development of ESRD, which
can further be characterized by fatigue and high blood pressure3-12. Additionally, modern metrics
identify glomerulonephritis as another characterizing feature of Alport Syndrome12. The

disease’s first documented discovery was in 1927 by a researcher named Cecil A. Alport, for
whom the disease is named, in one particular family that tended to display some, if not all of
these aforementioned symptoms through multiple generations20. This particular study was a
combination of information provided by the family themselves, along with corroborating
observations and relatively qualitative (rather than quantitative) data simply due to the time
when this disease was discovered; after genetics had a foundation, but before sequence
specificity or even nucleic acid structure had been elucidated. Fortunately for future
researchers, this immediate family was observable over multiple generations rather than just
one, which can sometimes hinder other case studies, and this is particularly important for this
genetics study because it exhibits a pattern of inheritance that other types of studies, such as
today’s in vitro sequence modification can never account for. Results of this paper were crucial
both for determining a mode of inheritance for this form of AS, as well as gathering a sense of
scale in both symptom severity and in timescale for the way this then-novel condition
progressed. For the case regarding this study, results pointed to an X-linked inheritance pattern
virtually identical to the one observed in Morgan’s Drosophila study, a notable attribute due to its
continuation of sex-linkage theories stemming from Morgan’s study. This is also important
because this would turn out to be the most prevalent form of AS, present in around 85% of
patients4,7,8,9,12. However, since survival rates in patients were so low and onset of renal failure
occurred so early for hemizygous males and phenotype expressing females with two mutant X
chromosomes, AS was difficult to study. For these same reasons, it was difficult to develop
treatment plans for such individuals simply because these efforts were more pioneering than
doctoring, and as the history of treatments for chronic kidney conditions will show in the
following section, advancements in such treatment technologies producing high success and
survival rates are quite novel, indeed.
Seminal Research in Kidney Disease

In order to understand today’s treatment methods, advancements, and explain why
kidney disease is still so prevalent, it is beneficial to observe how kidney disease was diagnosed
and treated in history. Given the aforementioned knowledge that kidney disease was relatively
unknown in the realm of medicine apart from passing observations until the 18th and 19th
centuries, more was discovered about the condition itself, including signs and symptoms, far
before treatment even became an option, a theme fairly universal regarding all diseases. Even
less would have been known to such contemporaries of the nature of heritable diseases. As
previously described, genetics and heritability only made their way into mainstream science at
the turn of the 20th century, and so in a sense the history of treatments for kidney disease is still
quite young, and also quite novel. Still, though, methods for screening and diagnosing disease
before attempting treatment are also important. For example, although observation of the urine
by the naked eye has always been possible throughout civilization, the advent of microscopy
allowed for a closer look at urine, and this is the first notable advancement in treatment
technology for nephrologists; with the ability to see smaller details, observers as early as the
late 16th century such as Nicolas-Claude Fabricius de Peiresc were able to describe crystals in
urine that are now known to likely represent uric acid, though with poor resolution and poor focal
lengths21. In a similar vein, the first descriptions of renal structure in general were elucidated by
then-novel microscopy observations by Marcello Malpighi in 166621. Briefly summarized,
microscopy is regarded here as the first step towards a myriad of other methods, evolving as a
method to accommodate the demands of other methodologies, from simple magnification
lenses as employed in the 17th century to today’s most advanced machines.

Before the 20th century, the greatest breakthroughs in medicine regarding chronic
kidney disease, after the advent of the microscope, came from the works of scholars focused on
the microbiological states and signs of kidney disease. Among this cohort are the minds of the
aforementioned Richard Bright, as well as other pioneering scholars of clinical nephrology such

as William Bowman, John Bostock, Pierre Francois Rayer, and Friedrich Theodor von Frerichs,
whom are related through their universal usage of urine and blood analysis through either
macroscopy or microscopy, abetted by similar observations in biopsies and autopsies of
patients21,22,23. One of Bowman’s crowning works, published in 1842, detailed his findings
regarding the structure and function of a large portion of the glomerular capillary network in the
membrane of the kidney. Namely, the structure (altogether called a nephron) understood then
(and now) consists of a capillary network connected to distinct structures called renal tubules,
which parse blood through a capsule subunit (later named after Bowman) in order to remove
large macromolecules such as proteins22. Later, the last subunit of this network would be
described by anatomist Friedrich Gustav Jacob Henle in 1866 as a subsequent set of tubule
“loops” which serve to reintroduce filtered blood to the bloodstream and maintain homeostatic
conditions in the glomerular matrix as well as the filtered blood22,24. During the conduction of
Bowman’s and Henle’s experiments, these other pioneers in clinical nephrology were altogether
concerned with the pathology of the kidney; knowing that there was a diseased state and that it
was observable, Bright’s initial descriptions of macroscopic symptomatology related to kidney
diseases were one of the most crucial first steps taken into the clinical field, all without usage of
microscopy. Bright’s work also delineated kidney diseases into two classes based on how
“visible” the effects and symptoms were, though his admission that these classifications were
rather arbitrary lend themselves to the notion that until microscopy was prevalent, even the most
studied minds were held back by a lack of technology21,22.

In addition to the advent of microscopy, a growing interest in cellular and organismal
biology led to some other advancements in kidney research preceding the 20th century, one
being the new prevalence of cell staining and the observation of renal tissue in addition to the
urine. While Rayer’s papers noted the first presence of microscopic hematuria, published from
1839-1841, and helped pave the way for the discoveries noted by Bowman and Henle, these

were only made possible by a technique developed in 1837 by physiology professor Gabriel
Valentin. His technique would involve using carmine dyes to prepare thin layers of renal tissue
on glass slides, colored to highlight structural patterns and the form of the tissue, and
subsequently observed by microscopy these forms in a technique we know today as cell
staining21,22. In this initial version of the technique, the tissue could be trans-illuminated and the
overall structure could be observed, including various artifacts of kidney substructures and
abnormalities within these, such as accumulations of fats, proteins, or blood cells, now known
as casts, in the aforementioned renal tubules22. In time, of course, this technique would be
improved upon, and in 1869 Edwin Klebs’ introduction of paraffin embedding would render
methods using carmine and other cell dyes obsolete due to their inefficiency22. Additionally, like
any novel medical technology, preliminary “trials” such as what are shown in the works of
Valentin, Bowman, and Henle were precursors to the acceptance and introduction of cell
staining to clinical and/or medical mainstream technologies; virtually all clinical studies to the
point of 1850 and in that decade were performed with less-informative unstained tissues22.

One last important technology to take note of before the turn of the 20th century was the
advent of centrifugation and its subsequent uptake by clinical researchers in a multitude of
fields, including those concerned with renal disorders. Based on the idea of centrifugal forces,
the methodology of separating substances using these forces did not first evolve in a clinical
setting, but rather an agricultural one. A German brewer by the name of Antonin Prandtl had a
predicament: when he was trying to separate cream from milk, he found the process of settling
inefficient; in addition, allowing settling in such a time as 1864, before the first known production
of commercial pasteurizers, could mean the unintended development of microbes in the milk25.
Thus, Prandtl produced a dairy centrifuge in order to expedite the process of separating the
layers of milk into its heterogeneous state by order of density, a technique that would later
evolve in the 20th century to be used in general medicine, mainly with regards to separating

cells from patient serum24,26. Instances of this process with regards to Alport Syndrome will be
detailed as this review advances chronologically, but the first known use of a centrifuge for
analytical purposes was in 1925, with a machine produced by Theodor Svedberg that would
later earn him the Nobel Prize24.
The 20th Century and a Boom in Kidney Research
With the first half of the 20th century came vast swathes of new information, as
communication between scientists in other parts of the world was becoming easier and
information was becoming much more accessible. From further advancements in microscopy,
centrifugation, and genetics, as well as updates to old studies with this improving technology,
the amount of new and exciting milestones alone are almost too many to mention in this
relatively brief review. Beginning with the reclassification of renal diseases into what we
generally know them as today, a very important standardization for all future studies and a
foundation for all kidney research to gain its bearings, the foundational paper came about in
1914 from scientists Theodor Fahl and Franz Volhard which they called Die Bright’sche
Nierenkrankenheit, Klinik, Pathologie und Atlas, and refined on the observations made by Bright
by categorizing kidney diseases based on their mechanisms22. There are three such
classifications: Nephrosis, which covers degenerative diseases of the kidney; Nephritides, which
cover inflammatory diseases of the kidney; and chronic nephrosclerosis, which by
happenstance is the characteristic nature of Alport Syndrome22. In addition to the
aforementioned discovery of X-linked glomerular sclerosis in Alport Syndrome, which was
incorrectly labelled hereditary nephritis by Alport himself in 192720, other advancements before
1950 include advancements in microscopy technology. For example, Thomas Addis’ life work
revolved around renal cell observation in patients, including autopsy examinations of renal cells
and urine, where he noted the formation of “casts”, cylindrical structures indicative of
aggregation of blood cells or other macromolecules such as proteins, for the first time in papers

he published in 193121,22, which has subsequently become part of modern screening methods
for quantifying the progression of chronic kidney diseases.

In the 1950s, wherein screening methods using urine microscopy were more fully
understood and renal autopsy was a fully practiced feature of studying renal disease, the fact
that no active glomerular monitoring methodology existed or was popularized yet prompted the
next logical step, one which would become absolutely essential to any and all future treatments
and clinical trials: renal biopsy, an active monitoring of the disease state. Given the recently
published work of Addis, which details full progressions of dozens of patients from onset to postmortem observation, as well as the nature of certain chronic diseases such as Alport Syndrome
acting progressively, it quickly became essential to understand the entire progression of chronic
kidney diseases, rather than the end state alone. With this in mind, there was an attempt before
this decade to perform clinical biopsies of renal tissue; Nils Alwall, a Swedish renal pathologist,
successfully gathered samples from 13 individuals using renal needles to remove tissue
samples, but a patient’s death caused him to cease and he ended up publishing in 1952, rather
than when he was doing his research in 194421. Fortunately, in the interim between Alwall’s
work and his publication, the famous Claus Brun continued successful needle biopsies and
produced results along with Paul Iversen that were published in 195121. A common theme
among the technologies described so far, rapid development of biopsy techniques led to Robert
Kark’s innovation of using a cutting needle, the Vim Silverman design, rather than an aspiration
needle to draw renal samples more efficiently for study in the year 195421. Based upon the
understanding of these renal biopsy techniques, the first real progress into treating kidney
diseases, including Alport Syndrome, made its way into scientific discussion, and before any
other advancements in machinery such as computers or drug development, there were two key
solutions being developed to actively treat kidney disease and renal failure: dialysis, and kidney
transplantation.

With regards to the former treatment, dialysis is certainly far less invasive than full
transplantation, and ideally limits extraneous factors, such as individuals donating functioning
kidneys. The procedure, in its most basic operating definition, is to “clean the blood” of the
patient the requisite machine is attached to, and the initial version of said machine was invented
in 1943 by Willem Kolff, a Dutch nephrologist moved by witnessing patients suffering end-stage
renal failure27. In particular, this machine was suited to treating acute kidney failure rather than
disease, and only one of twelve initial treatments were temporarily successful, prompting Kolff to
improve his design during the 1950s, after immigration to the US27. It was there that Kolff’s
work, in addition to the advent of Teflon tubing, would lead to the development of what is known
today as hemodialysis by Dr. Belding Scribner, wherein an extraneous device, called a dialyzer,
is used to directly clean blood from the patient’s bloodstream before re-entry via tubular shunts
connected at the beginning of each regularly scheduled treatment27,28. The first successful longterm treatment, qualified as more than one year of survival after beginning dialysis, came in
1960 with patient Clyde Shields. Clyde survived a further 11 years after renal failure due to this
new continuous treatment and technology before dying of a myocardial infarction in 1971, a
common theme with two other patients who began treatment after Shields and survived 28 and
14 years, respectively28. To improve this initial version of long-term treatment (and while the
aforementioned patients were undergoing theirs), the shunts were upgraded with the use of
Teflon tips and thinner tubing, made of silicone elastomers, to make a more flexible shunt that
was simultaneously less prone to blood clots27,28. In the year 1962, an additional advancement
in hemodialysis came in the form of the introduction of arteriovenous fistula procedures, utilizing
a blood pump to remove blood from an easily accessible vein (such as a brachial vein), dialyze
the blood, and reintroduce the blood into another part of the body to avoid issues with access to
non-dialyzed blood with the use of shunts27. Thus, the use of shunts has been phased out.
While most hemodialysis was performed at dedicated clinics or hospital sectors during this time,

the sheer capacity of such centers was often a limiting factor for who could receive treatment
once the fledgling treatment gained attention and before its influence spread to other parts of
the country and the world28,29. So, when one of Scribner’s colleague’s friend’s daughters was in
need of dialysis but turned away due to lack of capacity, Scribner et al. were prompted with
creation of a hemodialysis machine for home usage, which they quickly developed, and
machines of this nature were soon an extremely popular method of treatment throughout the
latter half of the 1960s and onward, a now-standard practice in general27-29.

Around the same time, in 1959, another type of dialysis was first successfully used to
treat renal failure by one Dr. Richard Ruben in San Francisco that aimed to avoid the use of
mechanical machines entirely, instead relying on another portion of the patient’s body to bear
the responsibility of cleaning blood. This method would come to be called peritoneal dialysis
(PD), so called for the use of a patient’s own stomach lining, the peritoneum, to filter blood via
usage of an extraneous dialysate solution27,28,30-32. The ultimate goal of such a treatment was to
enable ambulatory care and subsequent outpatient treatment so that patients could function in a
normal capacity rather than receive inpatient care for dozens of hours a week, a staple of
hemodialysis that still permeates today28. While, like hemodialysis, attempts at PD began in the
1920s and 1930s, plagued by issues of sterility and inadequate materials, as well as nonstandardized dialysates, the only fully standardized treatments would begin in the 1960s with a
program headed by Fred Boer at the University of Washington30,31. With regards to peritoneal
dialysis, the introduction of a revolutionary catheter specifically designed to access the
peritoneal region which would allow for easy access to the important biological treatment
interface came in 1968 from the mind of Henry Tenckhoff, a colleague of Boer, who was the
major proponent in developing the first standardized PD program after Boer’s exit30,31. This
catheter was designed using a material based on silicone elastomers, the same kind used for
the shunts developed for earlier hemodialysis treatments as well as many other procedures

involving catheters, even today28,30. The first self-treatment using PD came in 1962 with an
automatically-cycling machine developed by Boer’s team for home use, which was quite
successful, and which led to later improvements in the 1970s, including the advent of a selfsterilizing system in 197227,28. Today, these particular types of dialysis are the most prevalent
treatments for patients whose kidneys are failing whilst on a waitlist to receive a potentially longterm solution: a kidney transplant.
Kidney Transplantation and Modern Immunosuppression
Much like hemodialysis and peritoneal dialysis, kidney transplantation was a burgeoning
wealth of experimental potential exploited heavily in the time between the Great War and World
War II. While kidney transplantation had been experimented with for decades prior, the
plausibility of performing human-to-human transplants was only realized in 1936, when the first
human-to-human transplant was attempted33. This kidney, along with one in a documented
attempted transplant in 1939 were both from deceased donors and failed less than a week after
their insertion; unsuccessful procedures21,27,33,34. It was clear that there was a fundamental issue
regarding why these kidneys were failing, and the research this prompted started in the throes
of World War II with results from researchers such as Sir Peter Madawar eventually uncovering
the issue: the body’s own reaction to foreign objects, such as a foreign organ. The crux of the
issue in this case was that the recognition of an exogenous kidney, the donor’s, caused the
body to produce an immune response very similar to those presented for any other condition or
disease, and the antibodies produced (whose mechanisms are only now being elucidated!)
would have the effect of destroying the new kidney, even though it was initially “healthy”. This
term is now known as “rejection”, called so because of the recipient’s body’s refusal to retain
this “invader”, and this phenomenon was one of the largest barriers to knock down in order to
achieve successful long-term transplant treatments for patients with kidney failure. Without
immunosuppression, the longest transplant-to-death timeline up until 1952 was a couple of days
at most, until one attempt using a deceased mother’s organ in a transplantation with her son led

to a survival period of 22 days and into the year 1953, lending additional credence to the idea
that genetic relatives might tolerate transplantation better27,31,32,34. In 1954, a transplant between
two identical twins produced promising results, as the transplanted kidney would survive eight
years without any form of immunosuppression32,33,34. As the kidney was genetically identical, the
clear differentiator became apparent; the immune system of the recipient was going to reject a
new kidney unless it was genetically identical, or the recipient’s immune system was
suppressed. At this point, research funding immunotherapies shifted into the spotlight, and by
1962 the first commercial immunosuppressant drug, known as azathioprine, would be
developed33,34,35. Thus, the first long-term, genetically unrelated kidney transplant procedure
would produce a kidney that survived for 21 months in the recipient’s body, a leap of more than
a year from the previous best result. This catapulted immunosuppressant research even further
into relevance, and in 1972 one Jean Borel introduced to the scene his discoveries on the
immunosuppressive qualities of a drug called cyclosporin, which more actively worked to
suppress patients’ immune systems35,36. Cyclosporin was approved by the FDA one year later
and became recognized at the time as the most successful immunosuppressant drug, though
this would not stop continuing research on drug development. Both azathioprine and
cyclosporine were (and still are) known to produce many side effects, including hypertension
and nausea in addition to tremors and numbness in the extremities12,33,34,35. Today, additional
drugs such as tacrolimus (Prograf), introduced in 1989 and approved by the FDA in 1994, have
become a common part of some transplant patients’ regimens due to the broader range of
treatment and dosages it offers, although the aforementioned azathioprine and cyclosporine are
still prevalent12,33,34,35.
Today’s Progress and Where It’s Headed
When genome sequencing and genetic counselling services entered the mainstream,
heritable diseases like Alport Syndrome gained some much-needed data and relevance,
prompting the creation of a dedicated database for all known mutations. Through genetic

sequencing, early observations by Alport himself were finally validated; through case studies of
patients with Alport Syndrome, three specific genes would stand out as the clear identifiers for
Alport Syndrome: COL4A3, COL4A4, and COL4A53-12. COL4A3 and COL4A4 are located on
chromosome 2 in humans, while COL4A5 is located on the X chromosome, and the latter is the
gene Alport had observed so many decades before, wholly responsible for the X-linked
inheritance pattern he’d observed. These three genes are responsible for the formation of one
specific structural protein found in the glomerular membrane, as well as in the eyes and the ears
called type IV collagen, and at this one specific variant that relies on the association of one copy
of each gene. For this reason, scientists call this version of type IV collagen a “matrix”, denoted
“IV (345)”. Other matrices of other subunits or types of collagen exist, but the aforementioned
matrix is specifically responsible for Alport Syndrome. Each of these genes encodes one
subunit of the overall collagen structure, and contains code for a collagenous region, repeating
a glycine-proline-proline amino acid residue pattern, until encoding a more globular structure at
the C-terminal end, named the non-collagenous (NC) region. To form a IV (345) matrix, one
copy of the 3, 4, and 5 subunits each non-covalently associate and allow their respective
collagenous regions to also associate, thus forming the structural protein in its wild-type
configuration. When an issue with any of the subunit genes prevents the NC region from being
translated, or otherwise disrupts the structure of either of these regions (usually the collagenous
region), the function of the structural protein is compromised, leading to the phenotypes
associated with Alport Syndrome. Modern therapies and new proposals related to Alport
Syndrome stem from this general basis, and since X-linked Alport Syndrome is most common,
most therapies are directly related to COL4A5.

New therapies for hereditary diseases are developing rapidly; since the 20th century,
advances in fields of protein engineering, genetics, biotechnology, and more access to scientific
resources, most notably with the advent of the Internet, have all been promoters of such rapid

growth in resource allocation to genetic diseases that this review paper would have trouble
describing each and every single one. Therefore, to cover a small sample of the newly proposed
therapies, this paper will be limited to two separate measures the scientific community is
currently undertaking with regards to Alport Syndrome: accurate modelling, and a special
technique revolving around RNA splicing called “exon skipping”. With regards to the former, an
advancement in monitoring techniques such as diet control and efficient CRISPR/Cas9mediated DNA repair has allowed researchers of Hashikami et al. to accurately model disease
progression in an orthological fashion to human Alport Syndrome using mouse models37. Mice
possess orthologous genes for collagen production that share conserved function to humans;
this would make sense considering that mice are around 87% genetically identical to humans3740

. By harvesting wild-type zygotes and exposing the single cell to a Cas9 system introducing a

mutation in a mouse’s orthologous COL4A5, then reintroducing the zygote to a pseudopregnant
mouse, the authors could alter mice to express Alport Syndrome phenotypes, and in contrast to
previous studies, these mice produced analogous disease progression profiles relative to both
symptom development and timeline as documented human cases. This research became the
basis for another study, by Yamamura et al., dealing with ameliorating the specific R471X (a
truncation mutation) mice that Hashikami et al. developed.

The study by Yamamura et al. noted that Hashikami et al. had created a superb
template, a sort of base system, for studies like theirs to be conducted efficiently, and without
necessitating the use of human patients or non-organismal cell lines (in vitro studies) to create
meaningful results41. In order to utilize the potential of the mouse studies, this study used mice
generated with the same experiment parameters as the previous study, but experimental mice
were additionally exposed to a mechanism designed to cause the ribosome to ignore the
specific codon encoding the “STOP” signal. This allowed a slightly truncated, but functional
version of the collagenous region to be produced41. Notably, this methodology would produce

functional type IV collagen in individuals who would not otherwise do so. The results of the
study showed great promise, and a pre-clinical trial in humans is now being developed. With
such advances in a field that knew no treatments less than one hundred years ago, the field to
Alport’s contemporaries is likely unrecognizable, but today’s best stand on the shoulders of
giants.
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